Just reported
From Kenvue's results release of 2026年10月30日; its quarterly report has since been filed.
Actual
$3.89B
+3.2% y/y
-1.7% q/q
Guided
—
No guide given
Actual
$0.22
+4.8% y/y
-8.3% q/q
Guided
—
No guide given
Actual
$706M
+12% y/y
+1.0% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →The themes Kenvue is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
売上構成比はquarter ended 2026-09-27の推計であり、提出された報告書の数字ではありません。
Tylenol
Nonprescription medicines for pain and fever.
Zyrtec
Medicines for allergy symptoms.
Nicorette
Products to help people stop smoking.
Neutrogena
Skin and hair care products, including face and body care.
Listerine
Mouthwash and other oral care products.
BAND-AID Brand
Adhesive bandages and other wound-care products.
Its brands include Tylenol and Zyrtec medicines, Neutrogena skin and hair care, Listerine mouthwash, and BAND-AID wound-care products. It sells through retail and online channels around the world. Kenvue has a pending agreement to combine with Kimberly-Clark, subject to remaining conditions and regulatory approvals.
Kenvue Inc. 自身が米国証券取引委員会(SEC)に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。
$19.31-1.3%10月30日 終値
2026年9月27日までの数値(2026年10月30日提出の10-Qより)
Kenvue sells nonprescription medicines to shoppers through pharmacies and retailers, alongside skin care, mouthwash, baby care and wound-care products.
Grade C+
株価の下の帯は各日付時点の評価で、その時点までに公開された書類だけで算出しています。
Kenvue Inc. の評価履歴 12 四半期のうち 2 四半期を表示しています。 残る 10 四半期は 2024年3月 まで遡ります。